Dr. Gal Ehrlich

Founder and Managing Director of Ehrlich & Fenster

Moderator of the Business and Taxation Aspects of IP session

Dr Ehrlich has a B.Sc. in biology and a Ph.D. in genetic engineering from the Hebrew University of Jerusalem and a degree in Law, LL.B., from Tel Aviv University Law School.
Since 1994, Dr. Ehrlich has been involved in the preparation and prosecution of patent applications in all high-tech fields, including, inter alia, biotech, agrotech, medicine, pharmaceuticals, computers, communications, physics, chemistry and medical devices.
In June 2000 Dr. Ehrlich founded Ehrlich & Partners, the fastest-growing IP firm in Israel. As of December 1st 2006, the firm of Fenster & Co. merged into Ehrlich & Partners, which was renamed Ehrlich & Fenster, a leading patent attorneys firm in Israel, which employs more than 100 employees.

The firm serves thousands of clients, including leading universities and academic institutions in Israel, as well as many well-known major companies and start-ups and private clientele. Ehrlich & Fenster is recognized and categorized by prestigious world surveys as a leading patent attorneys firm in Israel and has been ranked for three consecutive years in the first tier by Managing Intellectual Property magazine's World Survey and by Chambers & Partners. Dr. Ehrlich is also ranked individually in the first tier- Chambers & Partners ranked Dr. Gal Ehrlich as “Band I” patent attorney for several consecutive year; The IAM magazine has chosen Dr. Gal Ehrlich to be one of the 250 Worlds Leading IP Strategists for several successive year; The IAM patent 1000 2013 has also mentioned Dr. Gal Ehrlich to be “outstanding” and “singled out for his superb direction of a talented team”.
During 2007 Dr. Ehrlich, together with his brother Adv. Amit Ehrlich, founded IPTradeRTM, Israel's premier service for assisting high-tech companies and private patent owners in monetizing their IP assets. During the past four years IPTrade, headed by Adv. Ehrlich, completed an extraordinary amount of patent sale transactions.